Long-term Drug Treatment for Obesity: A Systematic and Clinical Review -

Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Information type: Systematic reviews
Source: Journal of the American Medical Association
Specialities: Nutritional and metabolic disorders
Summary
This review reported that obesity medications, when prescribed with lifestyle interventions, produce additional weight loss relative to placebo ranging from approximately 3% of initial weight for orlistat and lorcaserin to 9% for top-dose phentermine plus topiramate at 1 year.
UKMi comment
In the UK, only orlistat is available for the treatment of obesity. Topiramate is not licensed for obesity treatment.
Related links: